Eswar Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.85 Cr
- Satisfied Charges ₹ 1.69 Cr
- Revenue Growth 37.46%
- Profit Growth 45.02%
- Ebitda 38.01%
- Net Worth 50.15%
- Total Assets 44.44%
About Eswar Therapeutics
Eswar Therapeutics Private Limited (ETPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 April 2017 (Seven years and ten months 20 days old ). Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.85 Cr. The company has closed loans amounting to ₹1.69 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vikram Khungar, Raj Khurana, and Kashmiri Khunger serve as directors at the Company.
Company Details
- Location
Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24304CH2017PTC041467
- Company No.
041467
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Eswar Therapeutics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Khungar  | Director | 25-Jan-2019 | Current |
| Raj Khurana | Director | 01-Apr-2023 | Current |
| Kashmiri Khunger | Director | 28-Nov-2023 | Current |
Financial Performance of Eswar Therapeutics.
Eswar Therapeutics Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 37.46% increase. The company also saw a substantial improvement in profitability, with a 45.02% increase in profit. The company's net worth Soared by an impressive increase of 50.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eswar Therapeutics?
In 2024, Eswar Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elinza Pharmaceuticals Private LimitedVikram Khungar is a mutual person
Charges (Loans)
₹48.53 M
₹16.90 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 4.45 Cr
- Uco Bank : 0.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2024 | Hdfc Bank Limited | ₹0.70 M | Open |
| 23 Oct 2024 | Hdfc Bank Limited | ₹0.75 M | Open |
| 16 Dec 2023 | Hdfc Bank Limited | ₹0.77 M | Open |
| 19 Aug 2023 | Hdfc Bank Limited | ₹0.37 M | Open |
| 19 Aug 2023 | Hdfc Bank Limited | ₹0.37 M | Open |
How Many Employees Work at Eswar Therapeutics?
Eswar Therapeutics has a workforce of 140 employees as of Jan 22, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eswar Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eswar Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
